BREATH Trial Reduced Distress in Early Breast Cancer Survivors
the Cancer Therapy Advisor take:
The Breast Cancer E-Heath (BREATH) trial combined with care as usual (CAU) was associated with significantly less distress in patients compared to CAU alone, according to an article published online in Journal of Clinical Oncology.
The BREATH trial is a Web-based self-management intervention available to breast cancer survivors (BCSs) that provides support for the psychological adjustment after primary treatment. BREATH consists of 16 automated weekly modules covering issues survivors may face early on.
In this study, BCSs were assigned to receive CAU + BREATH (n = 70) or CAU alone (n = 80) 2 to 4 months post-treatment.
Results showed participants in the CAU + BREATH cohort experienced significantly less distress than those in the CAU alone group (−7.79; 95% CI: −14.31, −1.27; P=0.02), with a small-to-medium effect size (d=0.33). However, empowerment was not determined to be affected (−1.71; 95% CI: 5.20, −1.79; P=0.34).
Furthermore, it was observed that in low-distress BCSs, a higher number of individuals in the CAU + BREATH cohort (39 of 70 [56%]; 95% CI: 44.1, 66.8) displayed clinically significant improvement (P=0.03), compared with those in the CAU alone cohort (32 of 80 [40%]; 95% CI: 30.0, 51.0).
The authors noted that the reduced distress observed in patients primarily was not sustained during follow-up.
Breast Cancer E-Heath (BREATH) trial combined with care as usual associated with significantly less distress compared to CAU alone.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Immunotherapy in Glioblastoma: Peaks and Pits
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer